STOCK TITAN
  1. Home
  2. Sec-filings
  3. VCYT
  4. [Form 4] VERACYTE, INC. Insider Trading Activity

Veracyte (VCYT) director awarded 5,272 RSUs vesting over one year

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Miller Thomas F. reported acquisition or exercise transactions in this Form 4 filing.

VERACYTE, INC. director Thomas F. Miller received a grant of 5,272 shares of common stock in the form of restricted stock units on June 11, 2026. These units vest in full on the first anniversary of the grant date or immediately before the company’s next annual meeting of stockholders, whichever comes first, and also vest in full upon a change in control of the issuer. Following this award, Miller directly holds 31,100 shares of Veracyte common stock.

Positive

  • None.

Negative

  • None.
Insider Miller Thomas F.
Role null
Type Security Shares Price Value
Grant/Award Common Stock 5,272 $0.00 --
Holdings After Transaction: Common Stock — 31,100 shares (Direct, null)
Footnotes (1)
  1. [object Object]
RSUs granted 5,272 shares Restricted stock units awarded on June 11, 2026
Post-grant holdings 31,100 shares Common stock held directly after the award
Grant price $0.0000 per share Reported acquisition price for the RSU grant
Vesting timing 1-year anniversary or before next annual meeting Full vesting schedule for RSUs granted June 11, 2026
restricted stock units financial
"Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
change in control financial
"the restricted stock units vest in full in the event of a change in control of the Issuer"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
annual meeting of stockholders financial
"vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Miller Thomas F.
(Last)(First)(Middle)
6000 SHORELINE COURT
SUITE 300
(Street)
SOUTH SAN FRANCISCO CALIFORNIA 94080
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
VERACYTE, INC. [ VCYT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/11/2026A(1)5,272A$031,100D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. Restricted stock units awarded on June 11, 2026 vest in full on the first anniversary of the date of the grant or immediately prior to the Company's next annual meeting of stockholders, if earlier. In addition, the restricted stock units vest in full in the event of a change in control of the Issuer.
Remarks:
/s/ Jonathan Wygant, as attorney-in-fact06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Veracyte (VCYT) director Thomas F. Miller report in this Form 4?

Thomas F. Miller reported receiving 5,272 restricted stock units of Veracyte common stock on June 11, 2026. These units were granted at no cash cost per share and increased his direct holdings to 31,100 shares after the award.

How many Veracyte (VCYT) shares did Thomas F. Miller hold after the latest grant?

After the June 11, 2026 grant, Thomas F. Miller directly held 31,100 shares of Veracyte common stock. This total reflects the addition of 5,272 restricted stock units that were awarded to him and reported in the Form 4 filing.

When do Thomas F. Miller’s new Veracyte (VCYT) restricted stock units vest?

The 5,272 restricted stock units granted to Thomas F. Miller vest in full on the first anniversary of June 11, 2026. They can also vest earlier, immediately before Veracyte’s next annual meeting of stockholders if that occurs sooner than the anniversary date.

What happens to Thomas F. Miller’s Veracyte (VCYT) RSUs if there is a change in control?

If there is a change in control of Veracyte, the 5,272 restricted stock units granted to Thomas F. Miller vest in full. This means all units become fully vested upon such a change, according to the terms described in the Form 4 footnote.

Did Thomas F. Miller pay cash for the newly acquired Veracyte (VCYT) shares?

No, the reported acquisition price per share was $0.0000, indicating the 5,272 shares were received as a grant of restricted stock units. This reflects an award rather than an open-market purchase of Veracyte common stock.